1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e

Modify Date: 2024-01-02 15:17:15

1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e Structure
1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e structure
Common Name 1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e
CAS Number 75985-31-8 Molecular Weight 203.24000
Density 1.2g/cm3 Boiling Point 327ºC at 760 mmHg
Molecular Formula C11H13N3O Melting Point N/A
MSDS N/A Flash Point 151.6ºC

 Use of 1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e


Ciamexon is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.

 Names

Name 1-[(2-Methoxy-6-methyl-3-pyridinyl)methyl]-2-aziridinecarbonitril e
Synonym More Synonyms

  Biological Activity

Description Ciamexon is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.
In Vivo Ciamexon on the development of diabetes in BB rats. Ciamexon was given once daily for 6 days per week beginning with the age of 42 or 50 days up to 120 days. For comparison, cyclosporin A (10 mg/kg) was applied following the same protocol. At 1 mg/kg, Ciamexon administration led to the complete prevention of diabetes in females but was not beneficial in males. At 10 mg/kg the drug caused significant suppression of diabetes development in males but more pronounced in females. Both, a reduction in the incidence of diabetes and a delay in the onset of hyperglycemia was observed only in females. After administration of cyclosporin A none of the animals developed diabetes. Ciamexon treatment did not affect granulocyte and lymphocyte counts and subsets in the peripheral blood except for a tendency to suppress eosinophilia. The growth of animals was not retarded. It is concluded that Ciamexon seems to influence the autoimmune state of the BB rat resulting in partial suppression of the disease.[1]
References 1. Kiesel U, et al. Suppression of spontaneous insulin-dependent diabetes in BB rats by administration of ciamexone. J Immunopharmacol. 1986;8(3):393-406.

 Chemical & Physical Properties

Density 1.2g/cm3
Boiling Point 327ºC at 760 mmHg
Molecular Formula C11H13N3O
Molecular Weight 203.24000
Flash Point 151.6ºC
Exact Mass 203.10600
PSA 48.92000
LogP 1.04428
Index of Refraction 1.573

 Safety Information

HS Code 2933990090

 Customs

HS Code 2933990090
Summary 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

 Synonyms

1(2H)-Pyridinecarboxylic acid,6-cyano-3,4-dihydro-,methyl ester
2-Cyan-1-[(2-methoxy-6-methyl-pyridin-3-yl)-methyl]-aziridine
2-cyano-1-[(2-methoxy-6-methylpyridin-3-yl)-methyl]-aziridine
2-cyano-1,4,5,6-tetrahydro-1-pyridinecarboxylic acid methyl ester
Hot Compounds More...
Dichloromethane
CAS#:75-09-2
Polyacrylic acid
CAS#:9003-01-4
sodium carbonate
CAS#:497-19-8
Silicon dioxide
CAS#:7631-86-9
Triethanolamine
CAS#:102-71-6
Demeton
CAS#:126-75-0
Water
CAS#:7732-18-5
4-(4-Piperidinyl)morpholine dihydrochloride
CAS#:53617-35-9
Diclofenac sodium
CAS#:15307-79-6
Budesonide
CAS#:51372-29-3